Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026 in Padua, Italy. The event, hosted by the University of Padova, will focus on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is driving clinical progress.
The AEPC, founded in 1963, is the world’s largest association in congenital cardiology, uniting over 1,000 specialists from 32 European countries and beyond. This year’s scientific program underscores the growing role of AI in cardiac care, a trend that aligns with Ventripoint’s flagship product, VMS+™. The company will exhibit alongside its European distributor, AngioPro, to engage with clinicians from the global congenital cardiology community.
A key focus at the booth will be the ability of VMS+™ to track cardiac function over time in congenital heart disease (CHD) patients. This approach is supported by the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for longitudinal assessment of ventricular function.
Ventripoint’s priority for 2026 is accelerating the integration of VMS+™ into routine clinical practice. The latest release, VMS+™ 4.0, was designed to streamline workflows and reduce the time needed to generate assessments, making advanced cardiac analysis accessible at the point of care. At the first echocardiogram, VMS+™ provides volumetric cardiac measurements equivalent to MRI, supporting clinical decision-making throughout a patient’s lifetime.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
This announcement is significant because it highlights a tangible step toward integrating AI-driven diagnostics into standard care for CHD, a condition that affects millions worldwide. By enabling early and accurate assessment of cardiac function, VMS+™ has the potential to improve outcomes and reduce healthcare costs, addressing a critical need in pediatric and adult congenital cardiology.
